2019年9月3日 · We show that RSPO2 promotes liver tumor formation in vivo and in vitro and that RSPO2's oncogenic activity requires Hippo/Yap activation in hepatocytes. Both RSPO2 and YAP1 are suggested to represent novel druggable targets in Wnt‐driven tumors of the liver.

RSPO2 is overexpressed in HCC and promotes the activation of Wnt signaling and Hippo-YAP1 signaling. YAP1 overexpression, as well as Wnt overexpression, is required for RSPO2-induced tumor initiation and progression [34].

We show that RSPO2 promotes liver tumor formation in vivo and in vitro and that RSPO2's oncogenic activity requires Hippo/Yap activation in hepatocytes. Both RSPO2 and YAP1 are suggested to represent novel druggable targets in Wnt-driven tumors of the liver.

RSPO2 is overexpressed in HCC and promotes the activation of Wnt signaling and Hippo-YAP1 signaling. YAP1 overexpression, as well as Wnt overexpression, is required for RSPO2-induced tumor...

2024年8月7日 · YAP1可以通过调节皮质肌动球蛋白网络的形成，在组织张力和3D组织形状中发挥关键作用。 还有研究表明YAP1能通过抑制F-肌动蛋白聚合的Rho GTPase激活蛋白ARHGAP18起作用。

YAP1 promotes TEAD4 binding to the enhancer region of TIAM1, thereby activating TIAM1 expression, increasing RAC1 activity, and subsequently inducing invadopodia formation and metastasis in breast cancer 12.

2021年10月18日 · First, RSPO2 and RSPO3 gene fusions with concomitant enhanced expression have been identified in colon cancer patients, and proposed as an alternative driver of Wnt/β-catenin hyperactivation that...

In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes.

2025年1月8日 · Here we employ spatiotemporally controlled oncogene activation and tumor suppressor inhibition together with multiomics to unveil the processes underlying oral epithelial progenitor cell...

2019年9月3日 · We show that RSPO2 promotes liver tumor formation in vivo and in vitro and that RSPO2's oncogenic activity requires Hippo/Yap activation in hepatocytes. Both RSPO2 and YAP1 are suggested to represent novel druggable targets in Wnt-driven tumors of the liver.